Related Experiment Video
Updated: May 17, 2026
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Protocol for a multi-modal performance-profiling workflow of CAR T cell products
Sarah Schulenberg1, Michelle Loeser1, Michael Schmueck-Henneresse2
1Berlin Institute of Health (BIH) Center for Regenerative Therapies, Experimental Immunotherapy, BIH at Charité - Universitätsmedizin Berlin, Berlin 13353, Germany.
Abstract:
Functional characterization of engineered T cell products is essential for adoptive cell therapy development. Here, we present multi-modal profiling of CAR T cell products combining 33-marker full-spectrum flow cytometry (FSFC) with live-cell serial tumor-killing imaging. We describe steps for cell preparation, antibody staining, acquisition, serial killing assay, and integrated data analysis. This protocol is readily adaptable to other engineered T cell therapies. For complete details on the use and execution of this protocol, please refer to Schulenberg et al.1.